The poster data is incremental and does not change the binary risk/reward of the Phase 3 PARADIGM program. The recent activist 13D filings (Sept 9) add a layer of potential strategic change — watch for any activist-driven announcements or shareholder proposals. The next major catalyst is the Phase 3 readout for HLP003.
Price Chart
Executive Summary
Helus Pharma presented four posters at Psych Congress 2026, including 12-month efficacy data from its Phase 1/2a study of HLP003 for MDD and a trial-in-progress overview of the ongoing Phase 3 PARADIGM program. The data further characterize the clinical profile of HLP003, which has Breakthrough Therapy Designation from the FDA. This is a routine scientific update with no new binary catalyst or regulatory decision.
Key Facts
- Four posters presented at Psych Congress 2026 (Sept 15-19, New Orleans) on HLP003, an investigational deuterated psilocin analog for adjunctive MDD treatment.
- Posters include 12-month efficacy results from the completed Phase 1/2a study and a trial-in-progress overview of the ongoing Phase 3 PARADIGM program.
- HLP003 has Breakthrough Therapy Designation from the FDA.
- HLP004 is in Phase 2 for generalized anxiety disorder.
- Two SC 13D filings by Eric H.L. So and Paul Glavine were filed 12 days prior (Sept 9, 2026), indicating activist interest in Cybin Inc. (Helus Pharma's operating name).
Financial Impact
No financial data disclosed; clinical-stage company with no approved products or revenue.
Risk Factors
- Phase 3 PARADIGM trial may fail to meet primary endpoints, as is common in MDD adjunctive therapy trials.
- Regulatory approval is not guaranteed despite Breakthrough Therapy Designation.
- Activist filings could lead to board changes or strategic shifts, creating uncertainty.
- Company is pre-revenue and relies on equity financing, diluting existing shareholders.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.19 (+0.79%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.19 (−6.13%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.19 (−4.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers